(Q37825594)

23 August 2017

1 reference

title

Cytomegalovirus risk, prevention, and management in pediatric solid organ transplantation (English)

1 reference

23 August 2017

0 references

organ transplantation

1 reference

Judith M Martin

1

1 reference

23 August 2017

Lara A Danziger-Isakov

series ordinal

2

1 reference

23 August 2017

publication date

27 December 2010

1 reference

Pediatric Transplantation

23 August 2017

published in

1 reference

23 August 2017

volume

15

1 reference

23 August 2017

issue

3

1 reference

23 August 2017

page(s)

229-236

1 reference

Herpes Simplex Virus Hepatitis after Solid Organ Transplantation in Adults

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

Definitions of cytomegalovirus infection and disease in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

International consensus guidelines on the management of cytomegalovirus in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

Cytomegalovirus infections following renal transplantation--effects on antiviral prophylaxis: a report of the North American Pediatric Renal Transplant Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

The risk, prevention, and outcome of cytomegalovirus after pediatric lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

Risk factors for rejection and infection in pediatric liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

Variability in standard care for cytomegalovirus prevention and detection in pediatric lung transplantation: survey of eight pediatric lung transplant programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

Pharmacokinetics of ganciclovir in pediatric renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

Hematologic complications of anti-CMV therapy in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

Prevention of CMV disease in pediatric kidney transplant recipients: evaluation of pp67 NASBA-based pre-emptive ganciclovir therapy combined with CMV hyperimmune globulin prophylaxis in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

The value of immunoprophylaxis for cytomegalovirus infection with intravenous immunoglobulin in pediatric liver transplant recipients receiving a low-dose immunosupressive regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

Cytomegalovirus immunoglobulin decreases the risk of cytomegalovirus infection but not disease after pediatric lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

Utility of Leflunomide in the Treatment of Complex Cytomegalovirus Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-3046.2010.01454.X

10.1111/J.1399-3046.2010.01454.X

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference